Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A controlled trial of renal denervation for resistant hypertension.
Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. Bhatt DL, et al. N Engl J Med. 2014 Apr 10;370(15):1393-401. doi: 10.1056/NEJMoa1402670. Epub 2014 Mar 29. N Engl J Med. 2014. PMID: 24678939 Free article. Clinical Trial.
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. Bakris GL, et al. J Am Coll Cardiol. 2014 Sep 16;64(11):1071-8. doi: 10.1016/j.jacc.2014.05.012. Epub 2014 May 20. J Am Coll Cardiol. 2014. PMID: 24858423 Free article. Clinical Trial.
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Kandzari DE, et al. Eur Heart J. 2015 Jan 21;36(4):219-27. doi: 10.1093/eurheartj/ehu441. Epub 2014 Nov 16. Eur Heart J. 2015. PMID: 25400162 Free PMC article. Clinical Trial.
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. Bakris GL, et al. J Am Coll Cardiol. 2015 Apr 7;65(13):1314-1321. doi: 10.1016/j.jacc.2015.01.037. J Am Coll Cardiol. 2015. PMID: 25835443 Free article. Clinical Trial.
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial.
Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G; SYMPLICITY HTN-3 Investigators. Flack JM, et al. J Am Soc Hypertens. 2015 Oct;9(10):769-779. doi: 10.1016/j.jash.2015.08.001. Epub 2015 Aug 8. J Am Soc Hypertens. 2015. PMID: 26362830 Clinical Trial.
The truth and consequences of the COURAGE trial.
Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O'Neill WW, Waksman R, Williams DO, Popma JJ, Buchbinder M, Mehran R, Meredith IT, Moses JW, Stone GW. Kereiakes DJ, et al. J Am Coll Cardiol. 2007 Oct 16;50(16):1598-603. doi: 10.1016/j.jacc.2007.07.063. Epub 2007 Sep 17. J Am Coll Cardiol. 2007. PMID: 17936161 Free article.
Comparison of the use of hemodynamic support in patients ≥80 years versus patients <80 years during high-risk percutaneous coronary interventions (from the Multicenter PROTECT II Randomized Study).
Pershad A, Fraij G, Massaro JM, David SW, Kleiman NS, Denktas AE, Wilson BH, Dixon SR, Ohman EM, Douglas PS, Moses JW, O'Neill WW. Pershad A, et al. Am J Cardiol. 2014 Sep 1;114(5):657-64. doi: 10.1016/j.amjcard.2014.05.055. Epub 2014 Jun 18. Am J Cardiol. 2014. PMID: 25037676 Clinical Trial.
Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial.
Kovacic JC, Kini A, Banerjee S, Dangas G, Massaro J, Mehran R, Popma J, O'Neill WW, Sharma SK. Kovacic JC, et al. J Interv Cardiol. 2015 Feb;28(1):32-40. doi: 10.1111/joic.12166. J Interv Cardiol. 2015. PMID: 25689546 Free article. Clinical Trial.
560 results